HR1492-119

What This Bill Does

H.R. 1492 changes the Inflation Reduction Act Medicare negotiation timing rule for small-molecule drug products. Current law generally makes drug products eligible after at least 7 years of market approval and biologics after 11 years. The bill strikes the 7-year period for drug products and inserts 11 years, equalizing the period with biologics. The amendment takes effect as if it had been included in Public Law 117-169, making the change retroactive. The bill gives small-molecule manufacturers a longer pre-negotiation window before Medicare price negotiation can apply.

Who Benefits and How

Small-molecule drug manufacturers benefit because Medicare negotiation eligibility is delayed from 7 years to 11 years after approval. Pharmaceutical investors benefit from a longer expected market period before negotiated Medicare prices can apply. Drug research companies benefit if the longer window improves projected returns for small-molecule development. Brand-name pharmaceutical firms benefit from equalized treatment with biologics under the negotiation clock.

Who Bears the Burden and How

Medicare beneficiaries may face higher drug costs if negotiation is delayed for selected small-molecule drugs. CMS negotiation staff must adjust eligibility timing and retroactive implementation under the Drug Price Negotiation Program. Medicare Part D plans may pay higher prices for drugs that would otherwise have entered negotiation earlier. Federal taxpayers bear higher Medicare spending if delayed negotiation preserves higher prices longer.

Key Provisions

• Amends Social Security Act section 1192 to change the small-molecule approval period from 7 years to 11 years.
• Aligns small-molecule timing with the biologic negotiation eligibility period.
• Provides retroactive effect as if included in Public Law 117-169.
• Delays Medicare Drug Price Negotiation Program eligibility for affected drug products.